The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Response Assessment in Neuro-Oncology Clinical Trials
Open accessAbstract
Development of novel therapies for CNS tumors requires reliable assessment of response and progression. This requirement has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vascular permeability, such as antiangiogenic therapies. In addition, most tumors have a nonenhancing component that can be difficult to accurately quantify. To improve the response assessment in neuro-oncology and to standardize the criteria that are used for different CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established. This multidisciplinary international working group consists of neuro-oncologists, medical oncologists, neuroradiologists, neurosurgeons, radiation oncologists, neuropsychologists, and experts in clinical outcomes assessments, working in collaboration with government and industry to enhance the interpretation of clinical trials. The RANO working group was originally created to update response criteria for high- and low-grade gliomas and to address such issues as pseudoresponse and nonenhancing tumor progression from antiangiogenic therapies, and pseudoprogression from radiochemotherapy. RANO has expanded to include working groups that are focused on other tumors, including brain metastases, leptomeningeal metastases, spine tumors, pediatric brain tumors, and meningiomas, as well as other clinical trial end points, such as clinical outcomes assessments, seizures, corticosteroid use, and positron emission tomography imaging. In an effort to standardize the measurement of neurologic function for clinical assessment, the Neurologic Assessment in Neuro-Oncology scale was drafted. Born out of a workshop conducted by the Jumpstarting Brain Tumor Drug Development Coalition and the US Food and Drug Administration, a standardized brain tumor imaging protocol now exists to reduce variability and improve reliability. Efforts by RANO have been widely accepted and are increasingly being used in neuro-oncology trials, although additional refinements will be needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Self-citationOstrom, Q. T., Gittleman, H., Xu, J., Kromer, C., Wolinsky, Y., Kruchko, C., & Barnholtz-Sloan, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now207 · Cited by 1,204
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Brandsma, D., Stalpers, L., Taal, W., Sminia, P., & van den Bent, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70125-6 · Cited by 1,121
Self-citationResponse assessment criteria for brain metastases: proposal from the RANO group
Lin, N. U., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., Bendszus, M., Brown, P. D., Camidge, D. R., Chang, S. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70057-4 · Cited by 1,088
Self-citationImmunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citationAlbert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C., Pope, W., Law, I., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 744
Self-citationMeningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
Rogers, L., Barani, I., Chamberlain, M., Kaley, T. J., McDermott, M., Raizer, J., Schiff, D., Weber, D. C., Wen, P. Y., & Vogelbaum, M. A. (2015) · Journal of Neurosurgery · doi:10.3171/2014.7.jns131644 · Cited by 698
Self-citationConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Self-citationMalignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology
Glass, J. P., Melamed, M., Chernik, N. L., & Posner, J. B. (1979) · Neurology · doi:10.1212/wnl.29.10.1369 · Cited by 493
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 476
Self-citationPseudoprogression and pseudoresponse in the treatment of gliomas
Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 378
Self-citationLeptomeningeal metastases: a RANO proposal for response criteria
Chamberlain, M., Junck, L., Brandsma, D., Soffietti, R., Rudà, R., Raizer, J., Boogerd, W., Taillibert, S., Groves, M. D., Rhun, E. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now183 · Cited by 317
Self-citationUpdates in the management of brain metastases
Arvold, N. D., Lee, E. Q., Mehta, M. P., Margolin, K., Alexander, B. M., Lin, N. U., Anders, C. K., Soffietti, R., Camidge, D. R., Vogelbaum, M. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now127 · Cited by 275
Self-citationComparison of Diameter and Perimeter Methods for Tumor Volume Calculation
Sorensen, A. G., Patel, S., Harmath, C., Bridges, S., Synnott, J., Sievers, A., Yoon, Y.-H., Lee, E. J., Yang, M. C., Lewis, R. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.551 · Cited by 270
Self-citationKaley, T., Barani, I., Chamberlain, M., McDermott, M., Panageas, K., Raizer, J., Rogers, L., Schiff, D., Vogelbaum, M., Weber, D., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not330 · Cited by 270
Self-citationThibault, I., Chang, E. L., Sheehan, J., Ahluwalia, M. S., Guckenberger, M., Sohn, M.-J., Ryu, S., Foote, M., Lo, S. S., Muacevic, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00166-7 · Cited by 253
Self-citationPatel, P., Baradaran, H., Delgado, D., Askin, G., Christos, P., John Tsiouris, A., & Gupta, A. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now148 · Cited by 250
Nayak, L., DeAngelis, L. M., Brandes, A. A., Peereboom, D. M., Galanis, E., Lin, N. U., Soffietti, R., Macdonald, D. R., Chamberlain, M., Perry, J., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox029 · Cited by 244
Self-citationEnd Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
van den Bent, M. J., Vogelbaum, M. A., Wen, P. Y., Macdonald, D. R., & Chang, S. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4998 · Cited by 240
Self-citationVogelbaum, M. A., Jost, S., Aghi, M. K., Heimberger, A. B., Sampson, J. H., Wen, P. Y., Macdonald, D. R., Van den Bent, M. J., & Chang, S. M. (2012) · Neurosurgery · doi:10.1227/neu.0b013e318223f5a7 · Cited by 234
Self-citationSystemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 223
Shah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195
Self-citationEllingson, B. M., Kim, H. J., Woodworth, D. C., Pope, W. B., Cloughesy, J. N., Harris, R. J., Lai, A., Nghiemphu, P. L., & Cloughesy, T. F. (2014) · Radiology · doi:10.1148/radiol.13131305 · Cited by 187
Chamberlain, M., Soffietti, R., Raizer, J., Ruda, R., Brandsma, D., Boogerd, W., Taillibert, S., Groves, M. D., Le Rhun, E., Junck, L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou089 · Cited by 163
Self-citationLin, N., Wefel, J. S., Lee, E. Q., Schiff, D., van den Bent, M. J., Soffietti, R., Suh, J. H., Vogelbaum, M. A., Mehta, M. P., Dancey, J. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70308-5 · Cited by 147
Self-citationThe use of amino acid PET and conventional MRI for monitoring of brain tumor therapy
Galldiks, N., Law, I. G., Pope, W. B., Arbizu, J., & Langen, K. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.12.020 · Cited by 141
Galanis, E., Buckner, J. C., Maurer, M. J., Sykora, R., Castillo, R., Ballman, K. V., & Erickson, B. J. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-005 · Cited by 139
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials
Avila, E. K., Chamberlain, M. C., Schiff, D., Reijneveld, J. C., Armstrong, T. S., Rudà, R., Wen, P. Y., Weller, M., Koekkoek, J. A. F., Mittal, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now190 · Cited by 139
Self-citationLin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Baumert, B. G., Brown, P. D., Camidge, D. R., Chang, S. M., Dancey, J. E., Gaspar, L. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70311-5 · Cited by 136
Self-citationClinical trial end points for high-grade glioma: the evolving landscape
Reardon, D. A., Galanis, E., DeGroot, J. F., Cloughesy, T. F., Wefel, J. S., Lamborn, K. R., Lassman, A. B., Gilbert, M. R., Sampson, J. H., Wick, W., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq203 · Cited by 123
Self-citationPseudoprogression in patients with glioblastoma: clinical relevance despite low incidence
Radbruch, A., Fladt, J. C., Kickingereder, P., Wiestler, B., Nowosielski, M., Baumer, P., Schlemmer, H., Wick, A., Heiland, S., Wick, W., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou129 · Cited by 118
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
Nowosielski, M., Wiestler, B., Goebel, G., Hutterer, M., Schlemmer, H. P., Stockhammer, G., Wick, W., Bendszus, M., & Radbruch, A. (2014) · Neurology · doi:10.1212/wnl.0000000000000402 · Cited by 114
Comparison of One-, Two-, and Three-Dimensional Measurements of Childhood Brain Tumors
Warren, K. E., Patronas, N., Aikin, A. A., Albert, P., & Balis, F. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1401 · Cited by 114
Ellingson, B. M., Leu, K., Pope, W. B., Lai, A., Nghiemphu, P. L., Liau, L. M., & Cloughesy, T. F. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov225.24 · Cited by 98
Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma
Shiroishi, M. S., Boxerman, J. L., & Pope, W. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov179 · Cited by 87
Warren, K. E., Poussaint, T. Y., Vézina, G., Hargrave, D. R., Packer, R. J., Goldman, S., Wen, P. Y., Pollack, I. F., Zurakowski, D., Kun, L. E., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24562 · Cited by 85
Self-citationPros and cons of current brain tumor imaging
Ellingson, B. M., Wen, P. Y., van den Bent, M. J., & Cloughesy, T. F. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou224 · Cited by 76
Self-citationHuang, R. Y., Rahman, R. M., Ballman, K. V., Felten, S. J., Anderson, S. K., Ellingson, B. M., Nayak, L., Lee, E. Q., Abrey, L. E., Galanis, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3040 · Cited by 75
Self-citationDynamic Susceptibility Contrast MR Imaging in Glioma
Boxerman, J. L., Shiroishi, M. S., Ellingson, B. M., & Pope, W. B. (2016) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2016.06.005 · Cited by 58
Emerging targeted therapies for glioma
Miller, J. J., & Wen, P. Y. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257609 · Cited by 57
Self-citationPhase 2 trial design in neuro-oncology revisited: a report from the RANO group
Galanis, E., Wu, W., Cloughesy, T. F., Lamborn, K. R., Mann, B., Wen, P. Y., Reardon, D. A., Wick, W., Macdonald, D., Armstrong, T. S., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70406-5 · Cited by 56
Self-citationWen, P. Y., Cloughesy, T. F., Ellingson, B. M., Reardon, D. A., Fine, H. A., Abrey, L. E., Ballman, K. V., Bendszuz, M., Buckner, J. C., Chang, S. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou226 · Cited by 53
Self-citationGahrmann, R., van den Bent, M. J., van der Holt, B., Vernhout, R. M., Taal, W., Vos, M. J., de Groot, J. C., Beerepoot, L. V., Buter, J., Flach, Z. H., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now311 · Cited by 51
Emerging techniques and technologies in brain tumor imaging
Ellingson, B. M., Bendszus, M., Sorensen, A. G., & Pope, W. B. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou221 · Cited by 46
Impact of imaging measurements on response assessment in glioblastoma clinical trials
Reardon, D. A., Ballman, K., Buckner, J. C., Chang, S. M., & Ellingson, B. M. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou286 · Cited by 41
Self-citationBlakeley, J. O., Coons, S. J., Corboy, J. R., Leidy, N. K., Mendoza, T. R., & Wefel, J. S. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov291 · Cited by 38
Boxerman, J. L., & Ellingson, B. M. (2015) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000054 · Cited by 23
Cited by
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationTracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Miller, A. M., Shah, R. H., Pentsova, E. I., Pourmaleki, M., Briggs, S., Distefano, N., Zheng, Y., Skakodub, A., Mehta, S. A., Campos, C., et al. (2019) · Nature · doi:10.1038/s41586-019-0882-3 · Cited by 628
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Kickingereder, P., Isensee, F., Tursunova, I., Petersen, J., Neuberger, U., Bonekamp, D., Brugnara, G., Schell, M., Kessler, T., Foltyn, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30098-1 · Cited by 454
Self-citationClinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Metadata
- Authors
- Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-07-20
- Volume
- 35
- Issue
- 21
- Pages
- 2439-2449
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2651525809
- Cited by
- 435
- References
- 55
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.